These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11709610)

  • 1. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.
    Miller FW; Rider LG; Chung YL; Cooper R; Danko K; Farewell V; Lundberg I; Morrison C; Oakley L; Oakley I; Pilkington C; Vencovsky J; Vincent K; Scott DL; Isenberg DA;
    Rheumatology (Oxford); 2001 Nov; 40(11):1262-73. PubMed ID: 11709610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Clinical Improvement in Adult and Juvenile Myositis.
    Rider LG; Giannini EH; Harris-Love M; Joe G; Isenberg D; Pilkington C; Lachenbruch PA; Miller FW;
    J Rheumatol; 2003 Mar; 30(3):603-17. PubMed ID: 12610824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies.
    Rider LG
    Rheum Dis Clin North Am; 2002 Nov; 28(4):935-77. PubMed ID: 12506779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.
    Huber AM; Feldman BM; Rennebohm RM; Hicks JE; Lindsley CB; Perez MD; Zemel LS; Wallace CA; Ballinger SH; Passo MH; Reed AM; Summers RM; White PH; Katona IM; Miller FW; Lachenbruch PA; Rider LG;
    Arthritis Rheum; 2004 May; 50(5):1595-603. PubMed ID: 15146430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies.
    van der Stap DK; Rider LG; Alexanderson H; Huber AM; Gualano B; Gordon P; van der Net J; Mathiesen P; Johnson LG; Ernste FC; Feldman BM; Houghton KM; Singh-Grewal D; Kutzbach AG; Alemo Munters L; Takken T;
    J Rheumatol; 2016 Jan; 43(1):169-76. PubMed ID: 26568594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical assessment in adult onset idiopathic inflammatory myopathy.
    Sultan SM
    Curr Opin Rheumatol; 2004 Nov; 16(6):668-72. PubMed ID: 15577602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies.
    Miller FW
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i82-5. PubMed ID: 22460145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group.
    Romich E; Saygin D; DiRenzo D; Mecoli CA; de Groot I; Lodin K; Regardt M; Sarver C; Kim JY; Park JK; Beer K; Needham M; Alexanderson H; Christopher-Stine L; de Visser M; Raaphorst J;
    Semin Arthritis Rheum; 2024 Oct; 68():152534. PubMed ID: 39159576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies.
    DiRenzo D; Bingham CO; Mecoli CA
    Curr Rheumatol Rep; 2019 Nov; 21(11):62. PubMed ID: 31741079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
    Rider LG; Feldman BM; Perez MD; Rennebohm RM; Lindsley CB; Zemel LS; Wallace CA; Ballinger SH; Bowyer SL; Reed AM; Passo MH; Katona IM; Miller FW; Lachenbruch PA
    Arthritis Rheum; 1997 Nov; 40(11):1976-83. PubMed ID: 9365086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies.
    Regardt M; Mecoli CA; Park JK; de Groot I; Sarver C; Needham M; de Visser M; Shea B; Bingham CO; Lundberg IE; Song YW; Christopher-Stine L; Alexanderson H
    J Rheumatol; 2019 Oct; 46(10):1351-1354. PubMed ID: 30770504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on outcome assessment in myositis.
    Rider LG; Aggarwal R; Machado PM; Hogrel JY; Reed AM; Christopher-Stine L; Ruperto N
    Nat Rev Rheumatol; 2018 May; 14(5):303-318. PubMed ID: 29651119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.
    Alexanderson H; Del Grande M; Bingham CO; Orbai AM; Sarver C; Clegg-Smith K; Lundberg IE; Song YW; Christopher-Stine L
    J Rheumatol; 2014 Mar; 41(3):581-92. PubMed ID: 24429182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis.
    Naveen R; Thakare DR; Agarwal V; Aggarwal R; Gupta L
    Clin Rheumatol; 2022 Mar; 41(3):765-772. PubMed ID: 34791543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and work impairment in idiopathic inflammatory myopathies in South Australia.
    Xu A; Sun C; Metcalf R; Limaye V
    Int J Rheum Dis; 2021 Jun; 24(6):809-814. PubMed ID: 33881230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.
    Isenberg DA; Allen E; Farewell V; Ehrenstein MR; Hanna MG; Lundberg IE; Oddis C; Pilkington C; Plotz P; Scott D; Vencovsky J; Cooper R; Rider L; Miller F;
    Rheumatology (Oxford); 2004 Jan; 43(1):49-54. PubMed ID: 12867580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies.
    Rider LG; Schiffenbauer AS; Zito M; Lim KL; Ahmed A; Zemel LS; Rennebohm RM; Passo MH; Summers RM; Hicks JE; Lachenbruch PA; Heyes MP; Miller FW;
    Clin Chem; 2002 Oct; 48(10):1681-8. PubMed ID: 12324484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pain on daily activities in patients with idiopathic inflammatory myopathies: Report from the OMERACT myositis working group.
    Saygin D; Alexanderson H; DiRenzo D; Raaphorst J; de Visser M; Ren D; Regardt M; de Groot I; Sarver C; Kim JY; Lodin K; Beer K; Needham M; Park JK; Christopher-Stine L; Mecoli CA
    Semin Arthritis Rheum; 2024 Aug; 67():152476. PubMed ID: 38851171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance between patient- and physician-reported disease activity in adult idiopathic inflammatory myopathy.
    Keret S; Saygin D; Moghadam-Kia S; Ren D; Oddis CV; Aggarwal R
    Rheumatology (Oxford); 2023 Dec; 62(12):3957-3961. PubMed ID: 37348555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.
    Ruperto N; Ravelli A; Murray KJ; Lovell DJ; Andersson-Gare B; Feldman BM; Garay S; Kuis W; Machado C; Pachman L; Prieur AM; Rider LG; Silverman E; Tsitsami E; Woo P; Giannini EH; Martini A; ;
    Rheumatology (Oxford); 2003 Dec; 42(12):1452-9. PubMed ID: 12832713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.